Hua Jin, MD Associate clinical professor, department of psychiatry, University of California, San Diego VA San Diego Healthcare System, San Diego, CA Jonathan M. Meyer, MD Assistant professor, department of psychiatry, University of California, San Diego VA San Diego Healthcare System, San Diego, CA
Medications such as olanzapine and clozapine carry substantial metabolic burdens but are effective treatments for some patients who do not respond to other antipsychotics. Elucidating mechanisms by which antipsychotic medications affect metabolic parameters remains important for:
quantifying patient risk
informing the frequency and targets of metabolic monitoring during antipsychotic therapy
permitting the development of novel agents without these limitations.
Related resource
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
Drug brand names
Amantadine • Symmetrel
Aripiprazole • Abilify
Clozapine • Clozaril
Haloperidol • Haldol
Nizatidine • Axid
Olanzapine • Zyprexa
Quetiapine • Seroquel
Risperidone • Risperdal
Ziprasidone • Geodon
Disclosures
Dr. Jin receives grant/research support from the National Institutes of Health, the National Institute of Mental Health, Otsuka Pharmaceuticals, and the Stanley Medical Research Foundation. He is a consultant to the Stanley Medical Research Foundation.
Dr. Meyer receives grant/research support from Bristol-Myers Squibb, the National Institutes of Health, the National Institute of Mental Health, and Pfizer Inc. He is a consultant to Bristol-Myers Squibb, Janssen Pharmaceutica, Organon USA (now Merck), Pfizer Inc., Vanda Pharmaceuticals, and Wyeth Pharmaceuticals (now Pfizer Inc.) and a speaker for AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, and Pfizer Inc.
